<p>N, number of patients; n, number of events; %, percentage based on N = 275.</p
<p>*The preferred adverse event term used for “CF exacerbation” was “cystic fibrosis.”</p><p>A patie...
<p>N, number of patients; n, number of AEs; AE, adverse event;</p><p>*, patients could appear in mor...
Introduction/Problem Definition In 1997, 33.6 million people entered the hospital hoping to improve ...
<p>Data are expressed in number (and percentage) of patients with adverse events.</p
Data presented as number of patients (proportion) or median [interquartile range].</p
Treatment-related adverse events occurring in ≥1% of the total population (SS).</p
<p>N, number of participants with at least one event.</p><p>Adverse events by system organ class and...
<p>Data are number (%) of patients with at least one adverse event. The safety population consisted ...
<p>Number and percentages of subjects showing adverse events after administration of drugs in differ...
<p>Most common treatment-related adverse events reported in ≥10% of patients.</p
<p>Serious adverse events in patients who completed all pharmacokinetic assessments (N = 25) and in ...
<p>Number of participants with at least one adverse event, and severity of the worst event per parti...
<p>N: Number of subjects inoculated; n: Number of subjects with adverse events; E: Number of adverse...
<p>The total number of reported episodes in all patients is compared to the number of patients who h...
<p>Treatment-emergent adverse events experienced by ≥5% of patients in either treatment group (treat...
<p>*The preferred adverse event term used for “CF exacerbation” was “cystic fibrosis.”</p><p>A patie...
<p>N, number of patients; n, number of AEs; AE, adverse event;</p><p>*, patients could appear in mor...
Introduction/Problem Definition In 1997, 33.6 million people entered the hospital hoping to improve ...
<p>Data are expressed in number (and percentage) of patients with adverse events.</p
Data presented as number of patients (proportion) or median [interquartile range].</p
Treatment-related adverse events occurring in ≥1% of the total population (SS).</p
<p>N, number of participants with at least one event.</p><p>Adverse events by system organ class and...
<p>Data are number (%) of patients with at least one adverse event. The safety population consisted ...
<p>Number and percentages of subjects showing adverse events after administration of drugs in differ...
<p>Most common treatment-related adverse events reported in ≥10% of patients.</p
<p>Serious adverse events in patients who completed all pharmacokinetic assessments (N = 25) and in ...
<p>Number of participants with at least one adverse event, and severity of the worst event per parti...
<p>N: Number of subjects inoculated; n: Number of subjects with adverse events; E: Number of adverse...
<p>The total number of reported episodes in all patients is compared to the number of patients who h...
<p>Treatment-emergent adverse events experienced by ≥5% of patients in either treatment group (treat...
<p>*The preferred adverse event term used for “CF exacerbation” was “cystic fibrosis.”</p><p>A patie...
<p>N, number of patients; n, number of AEs; AE, adverse event;</p><p>*, patients could appear in mor...
Introduction/Problem Definition In 1997, 33.6 million people entered the hospital hoping to improve ...
DOI
Add to ORKG